Earnings To Watch: Arcutis Biotherapeutics Inc (ARQT) Reports Q3 2024 Result [Yahoo! Finance]
Arcutis Biotherapeutics, Inc. - Common stock (ARQT)
Company Research
Source: Yahoo! Finance
The consensus estimate for Q3 2024 revenue is $37.62 million, and the earnings are expected to come in at -$0.43 per share. The full year 2024's revenue is expected to be $166.27 million and the earnings are expected to be -$1.58 per share. More detailed estimate data can be found on the Forecast page Warning! GuruFocus has detected 4 Warning Signs with ARQT. Over the past 90 days, revenue estimates for Arcutis Biotherapeutics Inc ( NASDAQ:ARQT ) for the full year 2024 have increased from $164.39 million to $166.27 million. However, estimates for 2025 have declined from $253.35 million to $248.50 million. Earnings estimates for the full year 2024 have improved from -$1.70 per share to -$1.58 per share, and for 2025, estimates have
Read more
Impact Snapshot
Event Time:
ARQT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARQT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARQT alerts
High impacting Arcutis Biotherapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
ARQT
News
- Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Arcutis to Present Two Posters at the 83rd American Academy of Dermatology Annual MeetingGlobeNewswire
- Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $13.00 to $15.00. They now have a "neutral" rating on the stock.MarketBeat
- Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.MarketBeat
- Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its price target raised by analysts at Mizuho from $20.00 to $21.00. They now have an "outperform" rating on the stock.MarketBeat
ARQT
Earnings
- 2/25/25 - Beat
ARQT
Sec Filings
- 2/25/25 - Form S-8
- 2/25/25 - Form 10-K
- 2/25/25 - Form 8-K
- ARQT's page on the SEC website